Review: Inhibitory potential of low molecular weight Heparin in cell adhesion; emphasis on tumor metastasis

Eur J Pharmacol. 2021 Feb 5:892:173778. doi: 10.1016/j.ejphar.2020.173778. Epub 2020 Dec 1.

Abstract

Low molecular weight heparin is a Heparin derivative, produced from commercial-grade Heparin through Chemical or enzymatic depolymerization. LMWH has remained a favored regimen for anticoagulation in cancer patients. Evidence from several studies has suggested that LMWHs possess antitumor and antimetastatic activity aside from their anticoagulant activity. Cancer metastasis is the foremost reason for cancer-related motility rate. Studies have pointed out that adhesion molecules play a decisive role in enhancing recurrent, invasive, and distant metastasis. Therefore, it is hypothesized that Cell adhesion molecules can be determined as a potential therapeutic target group, as antibodies or small-molecule inhibitors could easily access their extracellular domains. Furthermore, data from several investigations have reported LWMH potential effects as antimetastatic agents through influencing cell adhesion molecules. This review's objective is to emphasize the evidence available for the effects of the LMWHs in cell adhesion to inhibit tumor metastasis.

Keywords: Anti-adhesive; Anticoagulant; Cell adhesion molecules; LMWH; Metastasis.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Cell Adhesion / drug effects*
  • Cell Adhesion Molecules / metabolism*
  • Cell Movement / drug effects*
  • Heparin, Low-Molecular-Weight / pharmacology*
  • Humans
  • Neoplasm Invasiveness
  • Neoplasm Metastasis
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Neoplasms / pathology
  • Signal Transduction

Substances

  • Antineoplastic Agents
  • Cell Adhesion Molecules
  • Heparin, Low-Molecular-Weight